FM10 476
442
Adverse Disease Features in Gleason Score 3 4 “Favorable Intermediate-Risk” Prostate Cancer: Implications for Active SurveillanceA. Morlacco, J.C. Cheville, L.J. Rangel, D.J. Gearman, R.J. Karnes
Active surveillance might be an option for a selected subset of men with favorable
intermediate Gleason Score (GS) 3 4; however, clinical models alone have a limited
role in GS upgrade prediction in this setting, and alternative tools may warrant
further investigation.
448
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance StudyD.W. Lin, L.F. Newcomb, M.D. Brown, D.D. Sjoberg, Y. Dong, J.D. Brooks, P.R. Carroll, M. Cooperberg,
A. Dash, W.J. Ellis, M. Fabrizio, M.E. Gleave, T.M. Morgan, P.S. Nelson, I.M. Thompson, A.A. Wagner,
Y. Zheng, for the Canary Prostate Active Surveillance Study Investigators
In men undergoing active surveillance, the Four Kallikrein panel provides incremental
value over routine clinical information for prediction of high-grade cancer in the first
biopsy after diagnosis. These data support incorporation of emerging biomarkers in
models that aid in patient decision-making.
455
Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate CancerB.B. Anderson, D.T. Oberlin, A.A. Razmaria, B. Choy, G.P. Zagaja, A.L. Shalhav, J.J. Meeks,
X.J. Yang, G.P. Paner, S.E. Eggener
In over 2500 men who underwent radical prostatectomy for prostate cancer there
were no cases of seminal vesicle invasion with Gleason score 6 by current
International Society of Urological Pathology (ISUP) criteria. In addition, focal
extraprostatic extension with true Gleason score 6 was very rare (0.28%).
461
Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation StudyL. Dyrskjøt, T. Reinert, F. Algaba, E. Christensen, D. Nieboer, G.G. Hermann, K. Mogensen,
W. Beukers, M. Marquez, U. Segersten, S. Høyer, B.P. Ulhøi, A. Hartmann, R. Stöhr, S. Wach,
R. Nawroth, K. Schwamborn, C. Tulic, T. Simic, K. Junker, N. Harving, A.C. Petersen, J.B. Jensen,
B. Keck, M.-O. Grimm, M. Horstmann, T. Maurer, E.W. Steyerberg, E.C. Zwarthoff, F.X. Real,
N. Malats, P.-U. Malmström, T.F. Ørntoft
In a large prospective European study of non–muscle-invasive bladder cancer we
successfully validated a 12-gene real-time qualitative polymerase chain reaction
test for disease aggressiveness. The test showed independent prognostic power
beyond established risk factors, and may help in stratifying patients to optimal
treatment and follow-up regimens.
470
Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate CancerP.C. Albertsen
470
Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate CancerB. Hadaschik, K. Herrmann
471
Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate CancerD. D’Andrea, S.F. Shariat
472
Re: Lower Urinary Tract Symptoms and Incident Falls in Community Dwelling Older Men: The Concord Health and Ageing in Men ProjectD. Thomas, B. Chughtai
473
Re: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial CarcinomaE. Xylinas, A. Necchi on behalf of the Young Academic Urologists Urothelial Carcinoma Group of
the European Association of Urology
474
Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node InvolvementD. D’Andrea, S.F. Shariat
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 3 , S e p t emb e r 2 0 1 7
Words ofWisdom
Bladder Cancer
Original Articles
Prostate Cancer